In one click
The functional cure of HIV is one of the main challenges in the fight against it. Achieving a functional cure would cause patients to become carriers of the virus at undetectable levels, and although prevention measures would still be necessary, the risk of transmission would be minimized.
In order to achieve this functional cure, the HIVACAR project proposes the administration of a combination of immunotherapy that includes therapeutic vaccines (one of them customized for each patient to avoid the capability of the virus to escape from the vaccine), a potent antibody with the capacity to neutralize the site of binding of the virus with the cells that it infects and a latency reversing agent, that is, a molecule with the ability to unmask the virus.
It will be done within the framework of a Phase II clinical trial, to test the combination’s safety and tolerability. It will be determined whether this combination is capable of activating the immune system mechanisms necessary to remove infected cells from the latent viral reservoir. The socioeconomic and psychosocial impact of this treatment will also be analyzed. The main goal is to control HIV replication over long periods of time or throughout life without antiretroviral treatment.